News stories about SurModics (NASDAQ:SRDX) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SurModics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 43.9423842538025 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
SRDX stock opened at $37.15 on Wednesday. SurModics has a 1 year low of $21.90 and a 1 year high of $37.70. The stock has a market cap of $490.25, a P/E ratio of 88.45 and a beta of 0.75.
SurModics (NASDAQ:SRDX) last posted its quarterly earnings results on Thursday, February 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.15. SurModics had a net margin of 0.10% and a return on equity of 5.04%. The company had revenue of $17.01 million during the quarter, compared to analyst estimates of $17.69 million. analysts anticipate that SurModics will post -0.05 EPS for the current year.
In other SurModics news, VP Joseph J. Stich sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $33.53, for a total transaction of $33,530.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.70% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact SurModics (SRDX) Stock Price” was originally posted by BBNS and is the property of of BBNS. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://baseballnewssource.com/2018/03/21/surmodics-srdx-receiving-somewhat-favorable-media-coverage-report-finds/2027536.html.
SurModics Company Profile
Surmodics, Inc, together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and Ireland. It operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets.
Receive News & Ratings for SurModics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SurModics and related companies with MarketBeat.com's FREE daily email newsletter.